HGH vs Tesamorelin: What the Research Shows
HGH and Tesamorelin side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider HGH if…
- you want products with an FDA label: Genotropin (somatropin) is indicated for children with growth failure from inadequate growth hormone secretion[3]
- you want randomized data on lean mass in older men: Lean body mass increased with GH alone and with GH plus testosterone versus placebo; total body fat decreased only with the combination.[16]
Consider Tesamorelin if…
- you want a product with an FDA label: Egrifta is indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management[9]
- you want randomized data in HIV-associated lipodystrophy: Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo by the end of treatment.[15]
What they have in common
Spec comparison
Showing 9 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength are the same or both unknown.
| Field | HGH | Tesamorelin |
|---|---|---|
| Class | Recombinant growth hormone | GHRH analog |
| Also called | GH, growth hormone, generic HGH, IU | tesa, Egrifta |
| Category | Growth hormone | Growth hormone |
| FDA status | FDA approved (prescription only) | FDA approved (Egrifta) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.3)Growth hormone and its analogues and fragments are prohibited at all times (S2.2.3). | Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption. |
| Anti-doping detection | None reportedanti-doping literature, as of 2 Oct 2026 |
|
| Half-life | 0.4 hours IV; 3.0 hours subcutaneousintravenous (normal adults); subcutaneous (GHD adults), Genotropin · FDA label (Genotropin) | 11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Journal of applied physiology 2014, PMID 24235105 | Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101 |
| Human studies we summarised | 13 human (13 randomized or controlled) of 20 summarised | 12 human (11 randomized or controlled) of 16 summarised |
| Typical study doses |
|
|
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
HGH and Tesamorelin together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 7 results, 2 Oct 2026).
Giving growth hormone versus nudging the pituitary to make it
In a tesamorelin (TH9507) trial, IGF-I rose dose-dependently: +48% at 1 mg and +65% at 2 mg versus placebo.[17]
In a placebo-controlled GH trial, serum IGF-I was 293 on GH against 82 on placebo (micrograms per litre) at 6 months.[18]
A meta-analysis of tesamorelin 2 mg in HIV lipodystrophy reported reductions in visceral adipose tissue, waist circumference and trunk fat.[19]
Label contrasts
Genotropin is a recombinant human growth hormone indicated for children with growth failure due to growth hormone deficiency, among other uses.[3]
Tesamorelin's label is explicit that weight loss management is not an indication, since the drug has a weight-neutral effect.[9]
The tesamorelin label lists patients with active malignancy among its contraindications.[9]
Common questions
HGH vs tesamorelin: which is safer?
The rhGH meta-analysis in obese adults listed arthralgias (odds ratio 6), peripheral edema (5) and paresthesias (6.5) among adverse effects.[20]
Does tesamorelin replace growth hormone?
No study cited here tests tesamorelin as a replacement for growth hormone. In HIV patients it produced dose-related physiological increases in IGF-I.[17]
Can either be used for weight loss?
A meta-analysis of rhGH in obese adults reported decreased visceral adiposity and increased lean body mass without inducing weight loss.[20]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3GENOTROPIN (SOMATROPIN) KIT [PFIZER LABORATORIES DIV PFIZER INC]FDA label (Genotropin), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 4Effect of growth hormone on aging connective tissue in muscle and tendon: gene expression, morphology, and function following immobilization and rehabilitation.Journal of applied physiology (Bethesda, Md. : 1985) · 2014PMID 24235105Accessed 2 Oct 2026
- 5Impact of GH replacement therapy on sleep in adult patients with GH deficiency of pituitary origin.European journal of endocrinology · 2013PMID 23447518Accessed 2 Oct 2026
- 6Local administration of growth hormone stimulates tendon collagen synthesis in elderly men.Journal of applied physiology (Bethesda, Md. : 1985) · 2012PMID 22961272Accessed 2 Oct 2026
- 7An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 8Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 9EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 10The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 11Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 12The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 13PubMed search: (somatropin[tiab] OR "recombinant human growth hormone"[tiab] OR "recombinant growth hormone"[tiab] OR rhGH[tiab] OR "growth hormone therapy"[tiab] OR "growth hormone treatment"[tiab] OR "growth hormone replacement"[tiab] OR "growth hormone administration"[tiab] OR "GH therapy"[tiab] OR "GH treatment"[tiab] OR "GH replacement"[tiab] OR "GH administration"[tiab] OR "growth hormone injection"[tiab] OR "growth hormone injections"[tiab] OR "growth hormone supplementation"[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes.The Journal of clinical endocrinology and metabolism · 2005PMID 15784718Accessed 2 Oct 2026
- 15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 16The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial.The Journal of clinical endocrinology and metabolism · 2006PMID 16332938Accessed 2 Oct 2026
- 17A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.AIDS (London, England) · 2005PMID 16052083Accessed 2 Oct 2026
- 18Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults.European journal of endocrinology · 1994PMID 8180671Accessed 2 Oct 2026
- 19Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.Journal of the International Association of Providers of AIDS Care · 2026PMID 42538058Accessed 2 Oct 2026
- 20Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis.The Journal of clinical endocrinology and metabolism · 2009PMID 18940879Accessed 2 Oct 2026
Found an error? Report a correction.